News

Japanese investigators may have found a way of predicting which patients will develop intraocular inflammation in retrospective study.

According to the company, the device is designed to offer a non-surgical solution for patients suffering from keratoconus, corneal irregularities, photophobia, and presbyopia.

David A. Eichenbaum, MD, highlighted new therapies such as faricimab and high-dose aflibercept to reduce the burden of diseases like macular degeneration and diabetic eye conditions while improving patient outcomes during his presentation at EyeCon 2023.

MACs categorize goniotomy, canaloplasty, cyclophotocoagulation as experimental; glaucoma specialists speak out.

Patients considered vitamin D deficient had a risk of noninfectious uveitis more than twice that of their counterparts without vitamin D deficiency.

The company has come into agreement with IQVIA Services Japan G.K. as well as AUROLAB.

According to the company, its RELIEF Phase 2b trial will evaluate the efficacy and safety of licaminlimab in moderate-to-severe dry eye disease, and further explore the potential of a genetic biomarker. Topline results are expected in mid-2024.

A retrospective observational study shows BCVA was maintained after 6 months for patients with neovascular AMD

The company says top-line efficacy and safety data is on track for release in December of 2023.

According to the company, ATSN-101 continues to demonstrate clinically meaningful improvements in vision at the highest dose and is well-tolerated 12 months post-treatment.

The investigators wanted to determine if subclinical changes in the blood–aqueous barrier and the retinal physiology developed after anti-VEGF treatments with aflibercept, brolucizumab, and or faricimab .

The company announced key secondary endpoints were achieved with both EYP-1901 doses. These include a more than 80% reduction in treatment burden, with nearly two-thirds of eyes supplement-free up to 6 months.

Prevent Blindness is providing free geographic atrophy educational resources for patients, care partners and healthcare professionals, including a new episode of its Focus on Eye Health Expert series.

Sanjib Kumar Kar, MBBS, MD, was caught taking a bribe of ₹5,500 (~$65 USD) from a complainant to conduct surgery on his uncle.

The ranibizumab biosimilar is a recombinant antigen-binding fragment (Fab).

This retrospective, cross-sectional study identified all inpatients diagnosed with syphilitic uveitis in the US between 2010 and 2019.

The center includes about 30,000 square feet of space for rapid prototyping of new product designs, enhance manufacturing capabilities, and the expansion of research and development capabilities.

Moon Jeong Lee, MD, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, was honored as the recipient of the inaugural Visionary in Eye Care Resident Recognition Award for the category of Best in Ophthalmology during the EyeCon 2023 conference, December 1-2, at the Marriott Sanibel Harbour Resort and Spa in Sanibel, Florida.

Marta Stevanovic, MD, Massachusetts Eye and Ear, Harvard Medical School, Boston, was honored as the recipient of the inaugural Visionary in Eye Care Resident Recognition Award for the category of Best in Retina during the EyeCon 2023 conference, December 1-2, at the Marriott Sanibel Harbour Resort and Spa in Sanibel, Florida.

Analisa Arosemena, MD, underscores the importance of year-round glaucoma control through extended-release medications and laser treatments at EyeCon 2023.

Oluwatosin U. Smith, MD, and Peter J. McDonnell, MD, discuss their experience at EyeCon 2023, highlighting the latest updates in retina, cataract and refractive surgery, and the growing epidemic of myopia worldwide.

Jennifer Loh, MD, discusses the significance of maintaining a healthy ocular surface before surgery and exploring collaborative approaches for improved patient comanagement between ophthalmologists and optometrists at EyeCon 2023.

Benjamin Y Xu, MD, spoke with the Ophthalmology Times team about the real-world safety analysis of patients treated with intracanalicular dexamethasone insert using IRIS Registry at this year's American Academy of Ophthalmology meeting.

Rupa Wong, MD, spoke with the Ophthalmology Times team about Luminopia, the first FDA-approved digital therapeutic for amblyopia at this year's American Academy of Ophthalmology meeting.

Korean researchers reported Ptosis was associated with COVID-19 vaccination, while Guillain-Barré syndrome/Miller Fisher syndrome was associated with the COVID-19 infection.

Moving toward eliminating drug and chemical safety testing in animals.